相似文献
1
Aminothienopyridazines as imaging probes of tau pathology: a patent evaluation of WO2013090497.
Expert Opin Ther Pat. 2014 Mar;24(3):355-60. doi: 10.1517/13543776.2014.871526. Epub 2014 Jan 3.
2
In Vivo Comparison of Tau Radioligands F-THK-5351 and F-THK-5317.
J Nucl Med. 2017 Jun;58(6):996-1002. doi: 10.2967/jnumed.116.182980. Epub 2016 Nov 10.
3
Quantification of Tau Load in Alzheimer's Disease Clinical Trials Using Positron Emission Tomography.
Methods Mol Biol. 2018;1750:221-229. doi: 10.1007/978-1-4939-7704-8_15.
4
Tau Imaging in Alzheimer's Disease Diagnosis and Clinical Trials.
Neurotherapeutics. 2017 Jan;14(1):62-68. doi: 10.1007/s13311-016-0490-y.
5
Tau Positron Emission Tomography Imaging.
Cold Spring Harb Perspect Biol. 2017 May 1;9(5):a023721. doi: 10.1101/cshperspect.a023721.
6
Characteristics of Tau and Its Ligands in PET Imaging.
Biomolecules. 2016 Jan 6;6(1):7. doi: 10.3390/biom6010007.
7
Novel 18F-labeled arylquinoline derivatives for noninvasive imaging of tau pathology in Alzheimer disease.
J Nucl Med. 2013 Aug;54(8):1420-7. doi: 10.2967/jnumed.112.117341. Epub 2013 Jul 15.
8
PET Quantification of Tau Pathology in Human Brain with 11C-PBB3.
J Nucl Med. 2015 Sep;56(9):1359-65. doi: 10.2967/jnumed.115.160127. Epub 2015 Jul 16.
9
Preclinical Evaluation of F-RO6958948, C-RO6931643, and C-RO6924963 as Novel PET Radiotracers for Imaging Tau Aggregates in Alzheimer Disease.
J Nucl Med. 2018 Apr;59(4):675-681. doi: 10.2967/jnumed.117.196741. Epub 2017 Sep 28.
10
Brain metabolic correlates of CSF Tau protein in a large cohort of Alzheimer's disease patients: A CSF and FDG PET study.
Brain Res. 2018 Jan 1;1678:116-122. doi: 10.1016/j.brainres.2017.10.016. Epub 2017 Oct 21.
引用本文的文献
1
Pharmacological Modulators of Tau Aggregation and Spreading.
Brain Sci. 2020 Nov 13;10(11):858. doi: 10.3390/brainsci10110858.
本文引用的文献
1
Imaging of tau pathology in a tauopathy mouse model and in Alzheimer patients compared to normal controls.
Neuron. 2013 Sep 18;79(6):1094-108. doi: 10.1016/j.neuron.2013.07.037.
2
Early clinical PET imaging results with the novel PHF-tau radioligand [F18]-T808.
J Alzheimers Dis. 2014;38(1):171-84. doi: 10.3233/JAD-130098.
3
Novel 18F-labeled arylquinoline derivatives for noninvasive imaging of tau pathology in Alzheimer disease.
J Nucl Med. 2013 Aug;54(8):1420-7. doi: 10.2967/jnumed.112.117341. Epub 2013 Jul 15.
4
Design and selection parameters to accelerate the discovery of novel central nervous system positron emission tomography (PET) ligands and their application in the development of a novel phosphodiesterase 2A PET ligand.
J Med Chem. 2013 Jun 13;56(11):4568-79. doi: 10.1021/jm400312y. Epub 2013 May 28.
5
Aminothienopyridazines and methylene blue affect Tau fibrillization via cysteine oxidation.
J Biol Chem. 2013 Apr 19;288(16):11024-37. doi: 10.1074/jbc.M112.436006. Epub 2013 Feb 26.
6
[(18)F]T807, a novel tau positron emission tomography imaging agent for Alzheimer's disease.
Alzheimers Dement. 2013 Nov;9(6):666-76. doi: 10.1016/j.jalz.2012.11.008. Epub 2013 Feb 12.
7
Aminothienopyridazine inhibitors of tau aggregation: evaluation of structure-activity relationship leads to selection of candidates with desirable in vivo properties.
Bioorg Med Chem. 2012 Jul 15;20(14):4451-61. doi: 10.1016/j.bmc.2012.05.027. Epub 2012 May 23.
8
Inhibition of tau aggregation in a novel Caenorhabditis elegans model of tauopathy mitigates proteotoxicity.
Hum Mol Genet. 2012 Aug 15;21(16):3587-603. doi: 10.1093/hmg/dds190. Epub 2012 May 18.
9
The merits of FDDNP-PET imaging in Alzheimer's disease.
J Alzheimers Dis. 2011;26 Suppl 3:135-45. doi: 10.3233/JAD-2011-0008.
10
Discovery of brain-penetrant, orally bioavailable aminothienopyridazine inhibitors of tau aggregation.
J Med Chem. 2010 May 13;53(9):3739-47. doi: 10.1021/jm100138f.
Zotero 插件